Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis.

Eksteen B, Grant AJ, Miles A, Curbishley SM, Lalor PF, Hübscher SG, Briskin M, Salmon M, Adams DH.

J Exp Med. 2004 Dec 6;200(11):1511-7. Epub 2004 Nov 22.

2.

Lymphocyte homing in the pathogenesis of extra-intestinal manifestations of inflammatory bowel disease.

Eksteen B, Miles AE, Grant AJ, Adams DH.

Clin Med (Lond). 2004 Mar-Apr;4(2):173-80. Review.

PMID:
15139741
3.

Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease.

Adams DH, Eksteen B.

Nat Rev Immunol. 2006 Mar;6(3):244-51. Review.

PMID:
16498453
4.

Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease.

Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH.

Lancet. 2002 Jan 12;359(9301):150-7. Review.

PMID:
11809275
5.

Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis.

Borchers AT, Shimoda S, Bowlus C, Keen CL, Gershwin ME.

Semin Immunopathol. 2009 Sep;31(3):309-22. doi: 10.1007/s00281-009-0167-2. Epub 2009 Jun 17. Review.

6.

Primary sclerosing cholangitis: a clinical update.

Williamson KD, Chapman RW.

Br Med Bull. 2015 Jun;114(1):53-64. doi: 10.1093/bmb/ldv019. Epub 2015 May 16. Review.

PMID:
25981516
7.

Mucosal immunity in liver autoimmunity: a comprehensive review.

Trivedi PJ, Adams DH.

J Autoimmun. 2013 Oct;46:97-111. doi: 10.1016/j.jaut.2013.06.013. Epub 2013 Jul 25. Review.

PMID:
23891169
8.

Pathogenesis of primary sclerosing cholangitis.

Pollheimer MJ, Halilbasic E, Fickert P, Trauner M.

Best Pract Res Clin Gastroenterol. 2011 Dec;25(6):727-39. doi: 10.1016/j.bpg.2011.10.009. Review.

9.

Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.

Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD.

Gastroenterology. 2013 Sep;145(3):521-36. doi: 10.1053/j.gastro.2013.06.052. Epub 2013 Jul 1. Review.

10.

The Gut-Liver Axis in Primary Sclerosing Cholangitis.

Eksteen B.

Clin Liver Dis. 2016 Feb;20(1):1-14. doi: 10.1016/j.cld.2015.08.012. Epub 2015 Sep 26. Review.

PMID:
26593287
11.

Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.

Rojas-Feria M, Castro M, Suárez E, Ampuero J, Romero-Gómez M.

World J Gastroenterol. 2013 Nov 14;19(42):7327-40. doi: 10.3748/wjg.v19.i42.7327. Review.

12.

Autoimmune liver diseases and inflammatory bowel diseases in children: current issues and future perspectives.

Cardile S, Alterio T, Candusso M, Pietrobattista A, Liccardo D, Basso MS, Papadatou B, Bracci F, Knafelz D, Torre G.

Scand J Gastroenterol. 2017 Jun - Jul;52(6-7):662-667. doi: 10.1080/00365521.2017.1298833. Epub 2017 Mar 10. Review.

PMID:
28281846
13.

Role of beta7 integrins in intestinal lymphocyte homing and retention.

Gorfu G, Rivera-Nieves J, Ley K.

Curr Mol Med. 2009 Sep;9(7):836-50. Review.

14.

Hepatobiliary disease in inflammatory bowel disease.

Ahmad J, Slivka A.

Gastroenterol Clin North Am. 2002 Mar;31(1):329-45. Review.

PMID:
12122741
15.

Primary sclerosing cholangitis.

Williamson KD, Chapman RW.

Dig Dis. 2014;32(4):438-45. doi: 10.1159/000358150. Epub 2014 Jun 23. Review.

PMID:
24969292
16.

New Therapeutic Strategies for Primary Sclerosing Cholangitis.

Williamson KD, Chapman RW.

Semin Liver Dis. 2016 Feb;36(1):5-14. doi: 10.1055/s-0035-1571274. Epub 2016 Feb 12. Review.

PMID:
26870928
17.

Gut Homing Molecule Regulation of the Pathogenesis and Treatment of Inflammatory Bowel Diseases.

Evans-Marin HL, Cong Y.

Inflamm Allergy Drug Targets. 2015;14(1):4-12. Review.

PMID:
26296210
18.

Advances and controversies in the pathogenesis and management of primary sclerosing cholangitis.

Eksteen B.

Br Med Bull. 2014 Jun;110(1):89-98. doi: 10.1093/bmb/ldu008. Epub 2014 May 2. Review.

PMID:
24795363
19.

Inflammatory bowel disease of primary sclerosing cholangitis: a distinct entity?

Nakazawa T, Naitoh I, Hayashi K, Sano H, Miyabe K, Shimizu S, Joh T.

World J Gastroenterol. 2014 Mar 28;20(12):3245-54. doi: 10.3748/wjg.v20.i12.3245. Review.

20.

Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.

de Vries AB, Janse M, Blokzijl H, Weersma RK.

World J Gastroenterol. 2015 Feb 14;21(6):1956-71. doi: 10.3748/wjg.v21.i6.1956. Review.

Supplemental Content

Support Center